Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KOL Strategy

- PMLiVE

Pharma AI: how sales and marketing are starting to step out of R&D’s shadow

Traditionally R&D’s province, the meteoric rise of AI has turbo-charged discussions about how commercial organisations can make use of artificial intelligence

- PMLiVE

Therapy Watch launches new tracker covering Postpartum Depression

The new Therapy Watch Postpartum depression (PPD) study is the first tracker in the series to cover Psychiatry

Inizio

Hear from her: Message from the Women in Medicine Summit “Be the Change you Want to See”

Medscape Education

Hear from her: Changing what’s possible for Women in Healthcare

Medscape Education

Hear from her: Meet your hosts

Every day, women leaders are changing the healthcare landscape for the better. Our Women in Healthcare Leadership Podcast Series features some of the women working to elevate equity, achieve gender...

Medscape Education

- PMLiVE

MHRA extends licence of Vertex’s cystic fibrosis drugs for young children

Kaftrio and Kalydeco are now approved for use in certain patients aged two to five years

- PMLiVE

AstraZeneca’s Truqap plus Faslodex receives FDA approval for advanced breast cancer

About 290,000 people in the US will be diagnosed with breast cancer in 2023

- PMLiVE

National surveillance data reveals increase in antibiotic resistant infections in England

The number of deaths due to severe antibiotic resistant infections also increased in 2022

- PMLiVE

Connected devices: key considerations for pharmaceutical companies

How the use of data from connected drug delivery devices could help transform clinical trials

Let everyone have a say; the top 10 benefits of virtual advisory boards

Here's another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #7. Everyone Gets a Say Another top benefit for the...

Impetus Digital

- PMLiVE

Value-based pricing reform: Strengthening the ‘front door’ to the Colombian pharmaceutical market

Authored by: Marc Garcia and Tania Rodrigues

Inizio

- PMLiVE

Bristol Myers Squibb’s lung cancer drug Augtyro receives FDA approval

The drug was added to BMS’ portfolio last year through its $4.1bn acquisition of Turning Point

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links